Improving the manufacturing of cell therapies for cancer treatment.
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
This study is working on a new way to make cancer treatments using your own cells or donated cells, with the goal of making these therapies easier and faster to produce so more patients can get the help they need.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Proteios Technology, INC. NIH-funded |
| Lab location | 1 site (Issaquah, United States) |
| Project ID | NIH-10976161 on NIH RePORTER |
What this research studies
This research focuses on developing a new manufacturing system for autologous and allogeneic cell therapies, which are promising treatments for cancer. The approach aims to create a fully-automated system that can process multiple cell therapies simultaneously, significantly increasing the availability of these treatments. By isolating, activating, genetically modifying, expanding, and formulating cell-based therapies in a controlled environment, the project seeks to reduce the time and cost associated with current manufacturing methods. Ultimately, this innovation aims to make cell-based therapies more accessible to patients by allowing for point-of-care applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer who may benefit from autologous or allogeneic cell therapies.
Not a fit: Patients who do not have cancer or are not eligible for cell-based therapies may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could make advanced cell-based therapies more widely available and affordable for cancer patients.
How similar studies have performed: Other research has shown promise in automating cell therapy manufacturing, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
Issaquah, United States
- Proteios Technology, INC. — Issaquah, United States (Active)
Researchers
- Principal investigator: Snyder, Bob — Proteios Technology, INC.
- Study coordinator: Snyder, Bob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.